AU2017364901A1 - Compounds and their methods of use - Google Patents

Compounds and their methods of use Download PDF

Info

Publication number
AU2017364901A1
AU2017364901A1 AU2017364901A AU2017364901A AU2017364901A1 AU 2017364901 A1 AU2017364901 A1 AU 2017364901A1 AU 2017364901 A AU2017364901 A AU 2017364901A AU 2017364901 A AU2017364901 A AU 2017364901A AU 2017364901 A1 AU2017364901 A1 AU 2017364901A1
Authority
AU
Australia
Prior art keywords
alkyl
optionally substituted
carbocyclyl
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017364901A
Other languages
English (en)
Inventor
Andrew Mark Griffin
Brian Edward Marron
Gabriel Martinez Botella
Kiran Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Praxis Precision Medicines Inc
Original Assignee
Praxis Precision Medicines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praxis Precision Medicines Inc filed Critical Praxis Precision Medicines Inc
Publication of AU2017364901A1 publication Critical patent/AU2017364901A1/en
Priority to AU2023282271A priority Critical patent/AU2023282271A1/en
Priority to AU2025237912A priority patent/AU2025237912A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2017364901A 2016-11-28 2017-11-28 Compounds and their methods of use Abandoned AU2017364901A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2023282271A AU2023282271A1 (en) 2016-11-28 2023-12-14 Compounds and their methods of use
AU2025237912A AU2025237912A1 (en) 2016-11-28 2025-09-23 Compounds and their methods of use

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662427044P 2016-11-28 2016-11-28
US62/427,044 2016-11-28
US201762458306P 2017-02-13 2017-02-13
US62/458,306 2017-02-13
US201762552073P 2017-08-30 2017-08-30
US62/552,073 2017-08-30
PCT/US2017/063533 WO2018098499A1 (en) 2016-11-28 2017-11-28 Compounds and their methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023282271A Division AU2023282271A1 (en) 2016-11-28 2023-12-14 Compounds and their methods of use

Publications (1)

Publication Number Publication Date
AU2017364901A1 true AU2017364901A1 (en) 2019-06-13

Family

ID=62195384

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2017364901A Abandoned AU2017364901A1 (en) 2016-11-28 2017-11-28 Compounds and their methods of use
AU2023282271A Abandoned AU2023282271A1 (en) 2016-11-28 2023-12-14 Compounds and their methods of use
AU2025237912A Pending AU2025237912A1 (en) 2016-11-28 2025-09-23 Compounds and their methods of use

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2023282271A Abandoned AU2023282271A1 (en) 2016-11-28 2023-12-14 Compounds and their methods of use
AU2025237912A Pending AU2025237912A1 (en) 2016-11-28 2025-09-23 Compounds and their methods of use

Country Status (14)

Country Link
US (3) US11629146B2 (enExample)
EP (2) EP4397308A3 (enExample)
JP (4) JP7105797B2 (enExample)
CN (2) CN110337295B (enExample)
AU (3) AU2017364901A1 (enExample)
BR (1) BR112019010880A2 (enExample)
CA (2) CA3281817A1 (enExample)
DK (1) DK3548033T3 (enExample)
ES (1) ES2992063T3 (enExample)
FI (1) FI3548033T3 (enExample)
HU (1) HUE068842T2 (enExample)
PL (1) PL3548033T3 (enExample)
PT (1) PT3548033T (enExample)
WO (1) WO2018098499A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3281817A1 (en) 2016-11-28 2026-03-02 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
IL309843B2 (en) * 2018-05-30 2026-05-01 Praxis Prec Medicines Inc History of [4,2,1]triazolo[3,4-a]pyridines and their use as sodium ion channel modulators
CA3110211A1 (en) 2018-08-20 2020-02-27 Rogcon, Inc. Antisense oligonucleotides targeting scn2a for the treatment of scn1a encephalopathies
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
WO2021039961A1 (ja) * 2019-08-30 2021-03-04 大日本住友製薬株式会社 縮環ピラゾール誘導体
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
PE20221280A1 (es) * 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos
JP7880201B2 (ja) * 2020-06-10 2026-06-25 アムジエン・インコーポレーテツド シクロプロピルジヒドロキノリンスルホンアミド化合物
WO2023036934A1 (en) * 2021-09-13 2023-03-16 Boehringer Ingelheim Vetmedica Gmbh Cyclopropyl-(hetero)aryl-substituted ethylsulphonylpyridine derivatives
KR20250005348A (ko) 2022-04-26 2025-01-09 프락시스 프리시젼 메디신즈, 인크. 신경 장애의 치료
WO2024077273A2 (en) * 2022-10-07 2024-04-11 Denali Therapeutics Inc. Compounds, compositions, and methods
WO2026082004A1 (zh) * 2024-10-14 2026-04-23 上海京新生物医药有限公司 稠合杂芳基衍生物及其制备方法与应用
CN119613413B (zh) * 2024-12-26 2026-02-06 上海皓元医药股份有限公司 一种非唑奈坦的制备方法

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
CA1080712A (en) * 1976-09-22 1980-07-01 Jay D. Albright Hypotensive agents
US4230705A (en) * 1976-09-22 1980-10-28 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazines and their uses in treating anxiety
US4112095A (en) * 1976-10-07 1978-09-05 American Cyanamid Company 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
US4242515A (en) 1979-03-28 1980-12-30 American Cyanamid Company Substituted 3-alkyl-6-phenyl-1,2,4-triazolo-[4,3-a]pyridines
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
GB9507348D0 (en) * 1995-04-08 1995-05-31 Knoll Ag Therapeutic agents
EP1301511A2 (en) 2000-07-14 2003-04-16 Bristol-Myers Squibb Pharma Company IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
JP4898445B2 (ja) * 2003-05-29 2012-03-14 シャイア エルエルシー 乱用抵抗性アンフェタミン化合物類
WO2005077953A1 (ja) * 2004-02-18 2005-08-25 Banyu Pharmaceutical Co., Ltd. 含窒素縮合へテロ芳香環誘導体
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
US20100088778A1 (en) 2005-06-16 2010-04-08 John Charles Mulley Methods of Treatment, and Diagnosis of Epilepsy by Detecting Mutations in the SCN1A Gene
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
US8198448B2 (en) 2006-07-14 2012-06-12 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
FR2915198B1 (fr) 2007-04-18 2009-12-18 Sanofi Aventis Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
BRPI0908428A2 (pt) 2008-02-06 2015-12-08 Gilead Sciences Inc uso de ranozalina para tratar a dor.
WO2010053757A1 (en) 2008-10-29 2010-05-14 Gilead Palo Alto, Inc. 2 -oxoquinoxalin blockers of the late sodium channel
WO2010074807A1 (en) 2008-10-30 2010-07-01 Gilead Palo Alto, Inc. 3, 4-dihydroquinolin-2 ( 1h ) -one derivatives as sodium channel modulators
US20100125091A1 (en) 2008-11-14 2010-05-20 Gilead Palo Alto, Inc. Substituted heterocyclic compounds as ion channel modulators
AU2009330821B2 (en) 2008-12-24 2015-06-11 Bial - Portela & Ca, S.A. Pharmaceutical compounds
JP5340798B2 (ja) 2009-05-07 2013-11-13 タイガースポリマー株式会社 地中埋設管の製造方法
HRP20131122T1 (hr) 2009-05-12 2013-12-20 Janssen Pharmaceuticals, Inc. Derivati 1,2,4-triazolo[4,3-a] piridina i njihova uporaba u lijeäśenju ili prevenciji neuroloških i psihijatrijskih poremeä†aja
HUE034911T2 (hu) * 2009-07-27 2018-03-28 Gilead Sciences Inc Fúzionált heterociklusos vegyületek mint ioncsatorna modulátorok
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
FR2953520B1 (fr) 2009-12-04 2011-11-25 Sanofi Aventis Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
EP2588197B1 (en) 2010-07-02 2014-11-05 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2012065297A1 (en) 2010-11-16 2012-05-24 Impact Therapeutics, Inc. 3-ARYL-6-ARYL-[1,2,4]TRIAZOLO[4,3-a]PYRIDINES AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
WO2012154760A1 (en) 2011-05-10 2012-11-15 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (enExample) 2011-07-01 2018-04-28
WO2013043925A1 (en) 2011-09-21 2013-03-28 Gilead Sciences, Inc. Sodium channel blockers reduce glucagon secretion
EP2760866B1 (en) 2011-09-27 2017-12-13 Genfit Derivatives of 6-substituted triazolopyridazines as rev-erb agonists
CN103122000B (zh) * 2012-09-03 2013-12-25 中美冠科生物技术（太仓）有限公司 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂
TWI574962B (zh) * 2012-11-14 2017-03-21 加拓科學公司 作爲ｐｉ３激酶調節劑的芳雜環化合物及其使用方法和用途
WO2014100764A2 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Methods of inhibiting prmt5
US20140329755A1 (en) 2013-05-01 2014-11-06 Gilead Sciences, Inc. Combination therapy for the treatment of arrhythmias or heart failure
KR102307566B1 (ko) 2013-06-21 2021-10-05 제니쓰 에피제네틱스 리미티드 신규한 바이사이클릭 브로모도메인 억제제
DK3035926T3 (da) 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
GB201321740D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
WO2015095370A1 (en) 2013-12-19 2015-06-25 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
WO2015157955A1 (en) 2014-04-17 2015-10-22 Abbvie Inc. Heterocyclic btk inhibit ors
US10030026B2 (en) * 2014-06-04 2018-07-24 Rugen Holdings (Cayman) Limited Difluoroethylpyridine derivatives as NR2B NMDA receptor antagonists
EP3159366B1 (en) 2014-06-20 2020-04-08 Mitsubishi Chemical Corporation Polycarbonatediol, method for producing same, and polyurethane produced using same
TWI713455B (zh) 2014-06-25 2020-12-21 美商伊凡克特治療公司 ＭｎＫ抑制劑及其相關方法
PE20161476A1 (es) 2014-06-26 2017-01-07 Hoffmann La Roche Derivados de indolin-2-ona o pirrolo-piridin-2-ona
JP2017001991A (ja) 2015-06-11 2017-01-05 大日本住友製薬株式会社 新規ベンズオキサゾロン化合物
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
TW201819376A (zh) 2016-10-06 2018-06-01 比利時商健生藥品公司 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途
CA3281817A1 (en) 2016-11-28 2026-03-02 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098491A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018098500A1 (en) 2016-11-28 2018-05-31 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11492345B2 (en) 2017-02-13 2022-11-08 Praxis Precision Medicines, Inc. Compounds and their methods of use
WO2018187480A1 (en) 2017-04-04 2018-10-11 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11278535B2 (en) 2017-08-15 2022-03-22 Praxis Precision Medicines, Inc. Compounds and their methods of use
IL309843B2 (en) 2018-05-30 2026-05-01 Praxis Prec Medicines Inc History of [4,2,1]triazolo[3,4-a]pyridines and their use as sodium ion channel modulators
EA202092908A1 (ru) 2018-09-28 2021-05-14 Праксис Пресижн Медсинз, Инк. Модуляторы ионных каналов
US11773099B2 (en) 2019-05-28 2023-10-03 Praxis Precision Medicines, Inc. Compounds and their methods of use
US11505554B2 (en) 2019-05-31 2022-11-22 Praxis Precision Medicines, Inc. Substituted pyridines as ion channel modulators
US11279700B2 (en) 2019-05-31 2022-03-22 Praxis Precision Medicines, Inc. Ion channel modulators
US11767325B2 (en) 2019-11-26 2023-09-26 Praxis Precision Medicines, Inc. Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators
JP2023503343A (ja) 2019-11-26 2023-01-27 プラクシス プレシジョン メディシンズ， インコーポレイテッド イオンチャネルモジュレーター
PE20221280A1 (es) 2019-11-27 2022-09-05 Praxis Prec Medicines Inc Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos

Also Published As

Publication number Publication date
CA3045121A1 (en) 2018-05-31
CN110337295A (zh) 2019-10-15
CA3281817A1 (en) 2026-03-02
US20230322790A1 (en) 2023-10-12
US20250163068A1 (en) 2025-05-22
CN116763791A (zh) 2023-09-19
AU2023282271A1 (en) 2024-01-18
US20210188852A1 (en) 2021-06-24
WO2018098499A1 (en) 2018-05-31
AU2025237912A1 (en) 2025-10-16
HUE068842T2 (hu) 2025-01-28
JP7801794B2 (ja) 2026-01-19
CA3045121C (en) 2025-12-16
JP7495962B2 (ja) 2024-06-05
EP4397308A2 (en) 2024-07-10
DK3548033T3 (da) 2024-07-15
JP2024100974A (ja) 2024-07-26
EP3548033A1 (en) 2019-10-09
EP3548033A4 (en) 2020-09-09
BR112019010880A2 (pt) 2019-10-01
EP3548033B1 (en) 2024-04-10
ES2992063T3 (es) 2024-12-09
EP4397308A3 (en) 2024-08-21
FI3548033T3 (fi) 2024-07-10
JP2022141773A (ja) 2022-09-29
US11629146B2 (en) 2023-04-18
JP2019535838A (ja) 2019-12-12
JP7105797B2 (ja) 2022-07-25
CN110337295B (zh) 2023-06-09
PL3548033T3 (pl) 2025-06-02
JP2026062794A (ja) 2026-04-10
PT3548033T (pt) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7801794B2 (ja) 化合物及びその使用方法
JP7603118B2 (ja) イオンチャネルモジュレーター
JP7576539B2 (ja) イオンチャネルモジュレーター
US11261188B2 (en) Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
US11731966B2 (en) Compounds and their methods of use
US11278535B2 (en) Compounds and their methods of use
WO2018098500A1 (en) Compounds and their methods of use
HK40013290A (en) Compounds and their methods of use
HK40013290B (en) Compounds and their methods of use
EA046738B1 (ru) Модуляторы ионных каналов

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted